Clinical Trials Logo

End-Stage Kidney Disease clinical trials

View clinical trials related to End-Stage Kidney Disease.

Filter by:

NCT ID: NCT01528800 Completed - Clinical trials for End-stage Kidney Disease

Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients

iPACK-HD
Start date: November 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if vitamin K supplementation three times per week reduces the progression of coronary artery calcification over 12 months in dialysis patients compared to placebo.

NCT ID: NCT01232257 Completed - Clinical trials for Chronic Kidney Disease

Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

Start date: July 2011
Phase: Phase 3
Study type: Interventional

Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after treatment with NAC.

NCT ID: NCT00976846 Completed - Clinical trials for End Stage Kidney Disease

Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration

Start date: June 2009
Phase: N/A
Study type: Interventional

The proposed study seeks to determine the appropriate balance between the removal of undesirable small molecular substances (urea, creatinine, phosphate) and large molecular substances (ß2-m) and the retention of important substances (e.g.albumin) for the Baxter Xenium XPH dialyzer type under defined therapeutic conditions of olHDF primarily concerning filtration flow rates in relation to blood flow/plasma water flow rates. Furthermore the possibility of the removal of certain protein-bound substances shall be investigated together with the impact of increasing ultrafiltration on the parameters of the micro-inflammation.

NCT ID: NCT00798993 Completed - Clinical trials for End Stage Kidney Disease

Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients

Start date: January 2009
Phase: Phase 4
Study type: Interventional

This study aims to examine the effect of 25 hydroxyvitamin D supplementation and a structured exercise program on the exercise capacity and quality of life of haemodialysis patients with 25 hydroxyvitamin D insufficiency.

NCT ID: NCT00792454 Completed - Clinical trials for Cardiovascular Disease

Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

Start date: October 2008
Phase: N/A
Study type: Interventional

The mortality rate of treated patients with end stage renal disease(ESRD)is 22 deaths patient-years at risk in 2006. Incident patients with ESRD are most vulnerable within the first 90 days of dialysis, with an annualized mortality rate of 50 deaths/100 patient years. The vast majority of these deaths are due to cardiovascular causes. As cardiac rehabilitation programs have shown a 20% reduction in one year overall mortality rate post myocardial infarction the investigator proposes that a similar type of rehabilitation program will also have a benificial effect on morbidity and mortality in patients with chronic kidney disease(CKD)and ESRD.The overall goal of this project is to study whether a renal rehabilitation program based on guided exercise implemented in patients with stage III and stage IV CKD can influence the mortality rate of these patients prior to and during the first 90 days of dialysis Hypothesis:The application of a guided exercise program (renal rehabilitation) instituted in patients with stage III or Stage IV CKD will decrease the mortality rate prior to the initiation of renal replacement therapy. Hypothesis:The application of renal rehabilitation during the late stages of CKD will decrease the mortality risk during the first 90 days of renal rehabilitation therapy. Hypothesis:A guided exercise program will have an immediate and prolonged effect on activity levels, mental health and adaption to chronic illness in patients with advanced CKD.

NCT ID: NCT00649298 Completed - Clinical trials for End Stage Renal Disease

A Clinical Trial of IntensiVE Dialysis

ACTIVE
Start date: May 2008
Phase: Phase 4
Study type: Interventional

This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.

NCT ID: NCT00509236 Completed - Clinical trials for Diabetes Mellitus, Type 2

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.

NCT ID: NCT00417339 Completed - Clinical trials for End Stage Kidney Disease

Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis

Start date: December 2006
Phase: N/A
Study type: Observational

Study on intradialytic kinetics of protein-bound uremic retention solutes during long nocturnal hemodialysis

NCT ID: NCT00143741 Completed - Clinical trials for End-Stage Kidney Disease

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

Start date: May 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients to decrease the antibodies in such a way, that it may become possible to safely transplant kidneys into them.